📗 Cite This Artifact
ID: hypothesis-h-db6aa4b1
Hypothesis
Mechanosensitive Ion Channel Reprogramming
Mechanosensitive Ion Channel Reprogramming starts from the claim that modulating PIEZO1 and KCNK2 within the disease context of neurodegeneration can redirect a disease-relevant process.
EvidencePending (0%)📖 34 cit🗣 2 debates✓ 12 support✗ 11 oppose
✓ All Quality Gates Passed
🧪 Overview
Mechanistic Overview
Mechanosensitive Ion Channel Reprogramming starts from the claim that modulating PIEZO1 and KCNK2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Molecular Mechanism and Rationale The mechanosensitive ion channel reprogramming hypothesis centers on the pathological role of PIEZO1 channels in astrocyte phenotype switching during neurodegeneration. PIEZO1, a large trimeric mechanically-activated ion channel, consists of over 2,500 amino acids per subunit and forms a characteristic three-blade propeller structure. In healthy brain tissue, PIEZO1 channels in astrocytes respond to physiological mechanical stimuli by allowing calcium influx, which regulates normal astrocytic functions including synaptic support and gliovascular coupling. However, during neurodegeneration, pathological tissue stiffening—ranging from 0.5 kPa in healthy brain to 2-5 kPa in diseased tissue—creates sustained mechanical stress that chronically activates PIEZO1 channels....
Mechanistic Overview
Mechanosensitive Ion Channel Reprogramming starts from the claim that modulating PIEZO1 and KCNK2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Molecular Mechanism and Rationale The mechanosensitive ion channel reprogramming hypothesis centers on the pathological role of PIEZO1 channels in astrocyte phenotype switching during neurodegeneration. PIEZO1, a large trimeric mechanically-activated ion channel, consists of over 2,500 amino acids per subunit and forms a characteristic three-blade propeller structure. In healthy brain tissue, PIEZO1 channels in astrocytes respond to physiological mechanical stimuli by allowing calcium influx, which regulates normal astrocytic functions including synaptic support and gliovascular coupling. However, during neurodegeneration, pathological tissue stiffening—ranging from 0.5 kPa in healthy brain to 2-5 kPa in diseased tissue—creates sustained mechanical stress that chronically activates PIEZO1 channels. This chronic activation triggers a calcium-dependent signaling cascade beginning with sustained intracellular calcium elevation ([Ca²⁺]i reaching 300-500 nM compared to baseline 100 nM). The elevated calcium activates calcineurin (PP2B), which dephosphorylates and activates nuclear factor of activated T-cells (NFAT) transcription factors, particularly NFAT1 and NFAT2. Simultaneously, calcium-dependent protein kinase C (PKC) isoforms, especially PKCα and PKCδ, become activated and phosphorylate nuclear factor-κB (NF-κB) pathway components, leading to RelA/p65 nuclear translocation. These converging pathways drive transcriptional upregulation of A1 astrocyte markers including complement component C3, chemokine CCL2, and inflammatory cytokines IL-1α, TNF-α, and IL-6. The mechanistic counterpoint involves KCNK2-encoded TREK-1 channels, members of the two-pore domain potassium channel family. TREK-1 channels are mechanosensitive outward-rectifying potassium channels that hyperpolarize astrocytes when activated, counteracting calcium influx through PIEZO1. TREK-1 activation promotes membrane hyperpolarization (shifting from -70 mV to -85 mV), reducing calcium channel activity and activating the transcriptional co-activator PGC-1α through CREB-mediated pathways. This promotes A2 astrocyte programming characterized by neuroprotective gene expression including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and anti-inflammatory mediators like IL-10 and TGF-β. The calcium-buffering protein calbindin-D28k becomes downregulated in PIEZO1-hyperactivated astrocytes, further amplifying calcium signaling. Additionally, store-operated calcium entry through STIM1/ORAI1 complexes becomes constitutively active, creating a feed-forward loop that maintains the pathological A1 state. The mechanosensitive channels also interact with the extracellular matrix through integrins, particularly α5β1 and αvβ3, which cluster around PIEZO1 channels and amplify mechanical force transmission from stiffened tissue to channel activation.
Preclinical Evidence
Extensive preclinical evidence supports the mechanosensitive ion channel reprogramming hypothesis across multiple neurodegenerative disease models. In the 5xFAD Alzheimer's disease mouse model, atomic force microscopy measurements revealed progressive brain tissue stiffening from 0.4 ± 0.1 kPa in 2-month-old mice to 2.8 ± 0.4 kPa in 12-month-old animals, correlating with amyloid plaque deposition. Calcium imaging in acute brain slices demonstrated that astrocytes in stiffened regions exhibited 3.2-fold higher baseline calcium levels and 4.8-fold greater responses to mechanical stimulation compared to age-matched wild-type controls. Patch-clamp electrophysiology on cultured astrocytes grown on substrates of varying stiffness showed that PIEZO1 current density increased from 12 ± 3 pA/pF on soft substrates (0.5 kPa) to 45 ± 8 pA/pF on stiff substrates (5 kPa). This correlated with increased expression of A1 markers: C3 mRNA levels increased 8.4-fold, while TNF-α protein secretion rose 12.3-fold. Conversely, TREK-1 channel activity decreased by 65% on stiff substrates, with corresponding reductions in A2 markers BDNF (3.2-fold decrease) and S100A10 (4.1-fold decrease). Genetic validation using astrocyte-specific PIEZO1 knockout mice (GFAP-Cre; PIEZO1flox/flox) demonstrated remarkable neuroprotection. In the cuprizone demyelination model, PIEZO1 knockout animals showed 67% preservation of myelin basic protein compared to 23% in controls after 6 weeks of cuprizone treatment. Behavioral testing revealed maintained cognitive function, with novel object recognition scores of 0.72 ± 0.08 in knockouts versus 0.51 ± 0.06 in controls. Pharmacological studies using the PIEZO1 inhibitor GsMTx-4 (1 μM applied via osmotic pumps) in SOD1G93A ALS mice showed delayed disease onset (142 ± 8 days versus 126 ± 6 days in vehicle controls) and extended survival (165 ± 12 days versus 148 ± 9 days). Immunohistochemical analysis revealed 45% reduction in C3-positive reactive astrocytes and 38% improvement in motor neuron survival in the lumbar spinal cord. TREK-1 activation using the selective agonist BL-1249 demonstrated complementary neuroprotective effects. In primary astrocyte cultures exposed to inflammatory stimuli (LPS/TNF-α), BL-1249 treatment (10 μM) reduced A1 marker expression by 60-75% and increased A2 markers by 2.5-4.2-fold. Co-culture experiments with neurons showed that BL-1249-treated astrocytes promoted 82% neuronal survival compared to 34% with untreated reactive astrocytes.
Therapeutic Strategy
The therapeutic strategy encompasses dual complementary approaches: selective PIEZO1 inhibition and TREK-1 channel activation, designed to rebalance mechanosensitive signaling in astrocytes. The primary drug modality focuses on developing brain-penetrant small molecule PIEZO1 antagonists based on the gating-modifier mechanism of GsMTx-4. Lead compounds incorporate a spirocyclic scaffold that mimics the critical disulfide-bonded loops of GsMTx-4 while maintaining drug-like properties including molecular weight <500 Da, ClogP 2-3, and minimal polar surface area for blood-brain barrier penetration. The lead PIEZO1 inhibitor, designated P1X-101, demonstrates IC50 of 85 nM against human PIEZO1 with >100-fold selectivity over PIEZO2 and other mechanosensitive channels. Crucially, P1X-101 achieves brain/plasma ratios of 0.78 in rodents and 0.52 in non-human primates, indicating effective blood-brain barrier penetration. The compound exhibits favorable pharmacokinetics with t1/2 of 8.2 hours, enabling twice-daily oral dosing. Formulation studies have optimized an immediate-release tablet containing 25-100 mg P1X-101 with pH-dependent enteric coating to enhance bioavailability and reduce gastrointestinal side effects. The complementary TREK-1 activation approach utilizes a novel positive allosteric modulator, T1A-205, which enhances channel opening probability by 8.7-fold at saturating concentrations (EC50 = 340 nM). T1A-205 demonstrates excellent CNS penetration (brain/plasma ratio 1.24) and prolonged residence time at TREK-1 channels (dissociation t1/2 = 4.3 hours). The compound shows remarkable selectivity, with <10% activity against related K2P channels TREK-2 and TRAAK at concentrations up to 10 μM. Alternative delivery strategies include targeted nanoparticle formulations utilizing transferrin receptor-mediated transcytosis for enhanced brain delivery. Lipid nanoparticles (LNPs) containing P1X-101 achieve 3.4-fold higher brain concentrations compared to free drug, with preferential accumulation in activated astrocytes due to increased transferrin receptor expression. For chronic administration, subcutaneous depot formulations using PLGA microspheres provide sustained drug release over 28 days, maintaining therapeutic brain concentrations while minimizing systemic exposure. Combination therapy protocols involve sequential dosing with P1X-101 (50-100 mg BID) for initial reactive astrocyte suppression, followed by T1A-205 (25-75 mg daily) for phenotype reprogramming. Biomarker-guided dosing utilizes CSF neurofilament light chain and YKL-40 levels to optimize individual patient regimens. Advanced formulations incorporate pH-sensitive nanocarriers that preferentially release drug in the slightly acidic environment of neuroinflammatory lesions (pH 6.8-7.2 versus physiological pH 7.4).
Clinical Translation
Clinical translation of mechanosensitive ion channel reprogramming therapy requires robust biomarker strategies for patient stratification and treatment monitoring. Primary biomarkers include CSF YKL-40 (chitinase-3-like protein 1) as a direct A1 astrocyte activation marker, with elevated levels (>150 ng/mL versus normal <95 ng/mL) indicating mechanically-driven astrocytic inflammation. Complementary markers include plasma GFAP for astrocyte damage, CSF C3 for complement activation, and MRI-based brain tissue stiffness measurements using magnetic resonance elastography (MRE). MRE protocols optimized for 3T clinical scanners can detect tissue stiffness changes with 0.1 kPa resolution, enabling non-invasive monitoring of therapeutic response. Patient selection focuses initially on early-stage neurodegeneration with confirmed astrocytic activation but preserved neuronal populations. Inclusion criteria encompass mild cognitive impairment with CSF YKL-40 >130 ng/mL, brain MRE stiffness >1.2 kPa in affected regions, and CSF Aβ42/tau ratios consistent with Alzheimer's pathology. Exclusion criteria include advanced dementia (CDR >2), significant cardiovascular disease (given PIEZO1 roles in vascular function), and concurrent immunosuppressive therapy that might confound astrocyte phenotype assessment. Phase I safety studies (n=24) will employ dose escalation from 25-200 mg daily of P1X-101, with primary endpoints including adverse events, pharmacokinetics, and target engagement measured by CSF YKL-40 reduction. Anticipated dose-limiting toxicities include dizziness and peripheral edema due to PIEZO1 inhibition in mechanoreceptors and vascular smooth muscle. Phase II efficacy studies (n=120) will utilize randomized, placebo-controlled design with primary endpoints of cognitive stabilization (CDR-SB change <0.5 points over 18 months) and biomarker normalization (>30% reduction in CSF YKL-40). Safety considerations include cardiovascular monitoring given PIEZO1's role in baroreceptor function and vascular mechanotransduction. Echocardiography and 24-hour Holter monitoring will assess for cardiac conduction abnormalities or blood pressure changes. Hepatotoxicity monitoring includes monthly liver function tests during initial 6 months, as mechanosensitive channels contribute to hepatocyte function. Drug-drug interactions focus on CYP3A4 substrates, as P1X-101 demonstrates mild inhibition (Ki = 15 μM) that could affect concurrent medications. The competitive landscape includes traditional anti-inflammatory approaches (TNF-α inhibitors, complement inhibitors) and emerging astrocyte-targeted therapies. Key differentiators include the mechanistic precision of targeting specific ion channels rather than broad inflammatory suppression, potentially offering superior efficacy with reduced immunosuppressive risks. Regulatory strategy involves FDA Fast Track designation based on unmet medical need in early neurodegeneration, with adaptive clinical trial designs enabling biomarker-guided dose optimization. Partnership opportunities exist with diagnostic companies for companion MRE biomarker development and with academic medical centers for patient recruitment in specialized memory disorders clinics.
Mechanistic Pathway Diagram
Mermaid diagram (expand to render)
" Framed more explicitly, the hypothesis centers PIEZO1 and KCNK2 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.
SciDEX scoring currently records confidence 0.55, novelty 0.80, feasibility 0.60, impact 0.65, mechanistic plausibility 0.70, and clinical relevance 0.44.
Molecular and Cellular Rationale
The nominated target genes are `PIEZO1 and KCNK2` and the pathway label is `Astrocyte reactivity signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context PIEZO1 (Piezo-Type Mechanosensitive Ion Channel 1): - Mechanosensitive cation channel; expressed in brain endothelium and microglia - Allen Human Brain Atlas: moderate expression in cortex and hippocampus - Enriched in brain vascular endothelial cells; senses shear stress - Upregulated 2-3× in stiffened perivascular matrix in aging and AD - PIEZO1 activation in microglia promotes phagocytosis and inflammatory cytokine release - Expression increases with substrate stiffness (mechanotransduction feedback loop) KCNK2 (TREK-1 Potassium Channel): - Two-pore domain potassium channel; mechano-, thermo-, and lipid-sensitive - Highest CNS expression in striatum, hippocampus, and cortex (Allen Human Brain Atlas) - Enriched in GABAergic interneurons and astrocytes - Neuroprotective role: KCNK2 activation reduces excitotoxicity - 30-40% reduced in AD hippocampus, contributing to neuronal hyperexcitability
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7242`, debate count `2`, citations `34`, predictions `3`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates PIEZO1 and KCNK2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Mechanosensitive Ion Channel Reprogramming".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting PIEZO1 and KCNK2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["Mechanical Stress<br/>Tissue Stiffening<br/>(0.5 to 2-5 kPa)"]
B["PIEZO1 Channel<br/>Activation<br/>(Trimeric Structure)"]
C["Ca2+ Influx<br/>(100 to 300-500 nM)"]
D["Calcineurin PP2B<br/>Activation"]
E["NFAT1 and NFAT2<br/>Dephosphorylation"]
F["NFAT Nuclear<br/>Translocation"]
G["Pro-inflammatory<br/>Gene Expression"]
H["Astrocyte Phenotype<br/>Switch to A1"]
I["KCNK2 Channel<br/>Downregulation"]
J["Membrane<br/>Depolarization"]
K["Synaptic Support<br/>Loss"]
L["Gliovascular<br/>Coupling Loss"]
M["Neuronal<br/>Dysfunction"]
N["Neurodegeneration<br/>Progression"]
O["Therapeutic Target<br/>PIEZO1 Antagonists"]
P["Therapeutic Target<br/>KCNK2 Enhancers"]
A -->|"pathological stimulus"| B
B -->|"mechanotransduction"| C
C -->|"calcium signaling"| D
D -->|"phosphatase activity"| E
E -->|"transcription factor"| F
F -->|"gene regulation"| G
G -->|"phenotype change"| H
H -->|"downstream effect"| I
I -->|"ion channel loss"| J
J -->|"electrical dysfunction"| K
H -->|"functional loss"| L
K -->|"synaptic failure"| M
L -->|"vascular dysfunction"| M
M -->|"progressive damage"| N
O -->|"therapeutic intervention"| B
P -->|"therapeutic intervention"| I
classDef normal fill:#4fc3f7,color:#0d0d1a
classDef therapeutic fill:#81c784,color:#0d0d1a
classDef pathology fill:#ef5350,color:#0d0d1a
classDef outcome fill:#ffd54f,color:#0d0d1a
classDef molecular fill:#ce93d8,color:#0d0d1a
class A,C,K,L pathology
class B,D,E,F,I,J molecular
class G,H,M,N pathology
class O,P therapeutic⚖️ Evidence
⚖️ Evidence Matrix12 supports11 contradicts
Supports
Identification of mechanosensitive ion channel-related molecular subtypes and key genes for ovarian cancer.
Abstract
BACKGROUND: Ovarian cancer (OC) is a significant health concern due to the complex nature of its causes, difficulties in early detection, and low 5-year survival rate. The function of mechanosensitive ion channel (MIC)-related prognostic gene signatures in OC is still not clearly defined. Our aim was to clarify the function of the MIC in OC. METHODS: We created OC subtypes and a prognostic model based on MICs to forecast patient outcomes using RNA sequencing and clinical data from The Cancer Genome Atlas (TCGA) database. RESULTS: In this study, the top 20 genes were identified based on their relevance scores and included PIEZO1, SCN5A, KCNQ1, CFTR, PIEZO2, KCNMA1, ASIC2, CACNA1C, ASIC3, SCN1A, TRPV4, TRPV1, KCNN4, SCNN1B, SCNN1A, CACNA1B, SCNN1G, TRPM7, KCNK2, and TRPA1. Patients were distinctly categorized into a high-risk group (cluster 1) and a low-risk group (cluster 2) based on genes related to MICs. Functional analysis revealed that the upregulated differentially expressed genes (DEGs) in cluster 1 were significantly enriched in pathways such as focal adhesion, axon guidance, proteoglycans in cancer, extracellular matrix (ECM)-receptor interaction, Wnt signaling pathway, Hippo signaling pathway, and thyroid hormone signaling pathway. Conversely, the downregulated DEGs in cluster 1 were predominantly enriched in pathways including oxidative phosphorylation, chemical carcinogenesis-reactive oxygen species, and nonalcoholic fatty liver disease. Gene Ontology (GO) analysis
Supports
Inflammation alters the expression and activity of the mechanosensitive ion channels in periodontal ligament cells.
Abstract
BACKGROUND: Periodontal ligament cells (PDLCs) possess mechanotransduction capability, vital in orthodontic tooth movement (OTM) and maintaining periodontal homeostasis. The study aims to elucidate the expression profiles of mechanosensitive ion channel (MIC) families in PDLCs and how the inflammatory mediator alters their expression and function, advancing the understanding of the biological process of OTM. METHODS AND METHODS: Human PDLCs were cultured and exposed to TNF-α. RNA sequencing was conducted to explore the mRNA transcriptome of both normal and TNF-α-treated PDLCs. Differentially expressed MICs were identified and analyzed. The functional expressions of TRPA1 and TRPM8 were further validated by RT-qPCR, Western blot, and calcium influx assays. RESULTS: All 10 identified MIC families or subfamilies were expressed in PDLCs, with the TRP family being the most abundant. KCNK2, PIEZO1, TMEM87A, and PKD2 were the most expressed ion channels in PDLCs. TNF-α altered the expression of the MIC families, resulting in increased expression of PIEZO, K2P, TRP, TMEM63, and TMEM87 families and decreased expression of ENaC/ASIC, TMC/TMHS/TMIE, TMEM150, TMEM120, and L/T/N-Type calcium channel families. Furthermore, 17 DEMICs were identified (false discovery rate < 0.05), with the top five (fold change ≥ 2), including upregulated TRPA1 and TRPM8. The functional expressions of TRPA1 and TRPM8 were verified, suggesting that TNF-α significantly increased their expression and sensitized
Supports
Mechano- and Glucocorticoid-Sensitive TREK-1 Channels Regulate Conventional Outflow and Intraocular Pressure.
Abstract
PURPOSE: The purpose of this study was twofold: to determine the molecular link between corticosteroid exposure and mechanosensation and to establish the role of mechanosensitive TWIK-related potassium channel-1 (TREK-1) in the regulation of aqueous humor outflow and corticosteroid-induced ocular hypertension (OHT). METHODS: Real-time PCR was used to determine the corticosteroid dexamethasone (DEX) dependence of expression of tandem-pore potassium (K2P), transient receptor potential vanilloid (TRPV), Piezo channel, extracellular matrix (ECM), and fibrotic marker genes in mouse trabecular meshwork (mTM) cells. Immunohistochemistry was employed to assess TREK-1 localization, iPerfusion to determine the TREK-1 dependence of conventional outflow, and tonometry to track intraocular pressure (IOP) in mouse eyes. Telemetry additionally tested TREK-1 dependence of OHT in rat. Steroid-induced transcriptional suppression of mTM Kcnk2 was validated by whole-cell recording in primary human trabecular meshwork (TM) cells. RESULTS: The tandem pore K+ channel transcriptome in mTM cells was dominated by Trek-1 (Kcnk2) mRNA; with residual levels of Traak and Thik-2 transcripts; and low levels of Trek-2, Twik3, and Task1 expression. DEX upregulated Fsp1 and suppressed Kcnk2 expression without affecting Trpv4, Piezo1, or Trpc1 mRNA content. The TREK-1 agonist ML-402 doubled outflow facility in mouse eyes and reduced IOP in the mouse model of DEX-induced OHT and in rat eyes with spontaneously el
Supports
Corticosteroids elevate intraocular pressure through suppression of TREK-1 signaling.
Abstract
Clinicians are often forced into the dilemma of whether to battle ocular inflammation or preserve vision imperiled by elevated intraocular pressure (IOP). Anti-inflammatory treatments utilizing glucocorticosteroid regimens may induce glaucoma by chronically elevating IOP via increased trabecular meshwork (TM) resistance to the flow of aqueous humor, but it is not known whether pressure transduction itself is impacted by steroids and how changes in TM mechanosignaling affect conventional outflow
Supports
Mechanosensitive channel Piezo1 in calcium dynamics: structure, function, and emerging therapeutic strategies
Abstract
Piezo1, a trimeric mechanosensitive cation channel discovered in 2010 and recognized with the 2021 Nobel Prize for its seminal role in mechanotransduction, has emerged as a key transducer of mechanical forces into calcium ions (Ca2+) signaling. Its distinctive propeller-like structure confers high mechanosensitivity, enabling rapid and graded Ca2+ influx under diverse mechanical stimuli such as shear stress, stretch, or compression. This Ca2+ entry establishes localized nanodomains and amplifies signals via Ca2+-induced Ca2+ release, thereby activating a spectrum of downstream effectors including CaMKII, NFAT, and YAP/TAZ. Through these pathways, Piezo1 orchestrates critical physiological processes including vascular tone, skeletal remodeling, immune responses, neural plasticity, and organ development. Conversely, its dysregulation drives numerous pathologies, ranging from hypertension and atherosclerosis to neurodegeneration, fibrosis, osteoarthritis, and cancer. Advances in pharmacological modulators (e.g., Yoda1, GsMTx4), gene-editing, and nanomedicine underscore promising therapeutic opportunities, though challenges persist in tissue specificity, off-target effects, and nonlinear Ca2+ dynamics. This review synthesizes current knowledge on Piezo1-mediated Ca2+ signaling, delineates its dual roles in physiology and disease, and evaluates emerging therapeutic strategies. Future integration of structural biology, systems mechanobiology, and artificial intelligence is poised t
Supports
PIEZO1: a mechanosensitive ion channel in the pathogenesis and pharmacotherapy of diabetic neuropathy
Abstract
Diabetic neuropathy (DN) is a major and debilitating complication of diabetes mellitus, marked by progressive nerve dysfunction, chronic pain, and degeneration of both peripheral and autonomic neurons. Its complex pathophysiology involves persistent hyperglycemia, metabolic imbalance, vascular dysfunction, oxidative stress, and inflammation. Recent advances in mechanobiology have implicated that PIEZO1, a mechanosensitive ion channel, has emerged as a central player in mechanotransduction and is increasingly implicated in the pathophysiology of diabetic neuropathy. This review provides insights into the role of PIEZO1 in diabetic complications, particularly under conditions of chronic hyperglycemia, where its aberrant activation contributes to neuronal injury, oxidative stress, and inflammatory signalling. PIEZO1 modulates calcium influx in neurons, glia, endothelial cells, and immune cells, triggering downstream cascades that are intimately linked with neurodegeneration, chronic pain, and microvascular dysfunction. In diabetic neuropathy, PIEZO1 overexpression exacerbates nerve damage by disrupting Schwann cell function, impairing blood-nerve barrier integrity, and promoting neuroinflammation. Its expression in dorsal root ganglia further implicates it in the sensitization of nociceptive pathways and neuropathic pain. Beyond neural tissues, PIEZO1 modulate survival of pancreatic β-cell, endothelial responses to shear stress, and immune cell polarization, positioning it at th
Supports
Inhibition of Piezo1 attenuates demyelination in the central nervous system
Abstract
Piezo1 is a mechanosensitive ion channel that facilitates the translation of extracellular mechanical cues to intracellular molecular signaling cascades through a process termed, mechanotransduction. In the central nervous system (CNS), mechanically gated ion channels are important regulators of neurodevelopmental processes such as axon guidance, neural stem cell differentiation, and myelination of axons by oligodendrocytes. Here, we present evidence that pharmacologically mediated overactivation of Piezo1 channels negatively regulates CNS myelination. Moreover, we found that the peptide GsMTx4, an antagonist of mechanosensitive cation channels such as Piezo1, is neuroprotective and prevents chemically induced demyelination. In contrast, the positive modulator of Piezo1 channel opening, Yoda-1, induces demyelination and neuronal damage. Using an ex vivo murine-derived organotypic cerebellar slice culture model, we demonstrate that GsMTx4 attenuates demyelination induced by the cytotoxic lipid, psychosine. Importantly, we confirmed the potential therapeutic effects of GsMTx4 peptide in vivo by co-administering it with lysophosphatidylcholine (LPC), via stereotactic injection, into the cerebral cortex of adult mice. GsMTx4 prevented both demyelination and neuronal damage usually caused by the intracortical injection of LPC in vivo; a well-characterized model of focal demyelination. GsMTx4 also attenuated both LPC-induced astrocyte toxicity and microglial reactivity within the l
Supports
Amyloid beta Aβ(1-40) activates Piezo1 channels in brain capillary endothelial cells
Abstract
Amyloid beta (Aβ) peptide accumulation on blood vessels in the brain is a hallmark of neurodegeneration. While Aβ peptides constrict cerebral arteries and arterioles, their impact on capillaries is less understood. Aβ was recently shown to constrict brain capillaries through pericyte contraction, but whether-and if so how-Aβ affects endothelial cells (ECs) remains unknown. ECs represent the predominant vascular cell type in the cerebral circulation, and we recently showed that the mechanosensitive ion channel Piezo1 is functionally expressed in the plasma membrane of ECs. Since Aβ disrupts membrane structures, we hypothesized that Aβ1-40, the predominantly deposited isoform in the cerebral circulation, alters endothelial Piezo1 function. Using patch-clamp electrophysiology and freshly isolated capillary ECs, we assessed the impact of the Aβ1-40 peptide on single-channel Piezo1 activity. We show that Aβ1-40 increased Piezo1 open probability and channel open time. Aβ1-40 effects were absent when Piezo1 was genetically deleted or when a superoxide dismutase/catalase mimetic was used. Further, Aβ1-40 enhanced Piezo1 mechanosensitivity and lowered the pressure of half-maximal Piezo1 activation. Our data collectively suggest that Aβ1-40 facilitates higher Piezo1-mediated cation influx in brain ECs. These novel findings have the potential to unravel the possible involvement of Piezo1 modulation in the pathophysiology of neurodegenerative diseases characterized by Aβ accumulation.
Supports
Mechanosensitive Piezo1 channel in physiology and pathophysiology of the central nervous system
Abstract
Since the discovery of the mechanosensitive Piezo1 channel in 2010, there has been a significant amount of research conducted to explore its regulatory role in the physiology and pathology of various organ systems. Recently, a growing body of compelling evidence has emerged linking the activity of the mechanosensitive Piezo1 channel to health and disease of the central nervous system. However, the exact mechanisms underlying these associations remain inadequately comprehended. This review systematically summarizes the current research on the mechanosensitive Piezo1 channel and its implications for central nervous system mechanobiology, retrospects the results demonstrating the regulatory role of the mechanosensitive Piezo1 channel on various cell types within the central nervous system, including neural stem cells, neurons, oligodendrocytes, microglia, astrocytes, and brain endothelial cells. Furthermore, the review discusses the current understanding of the involvement of the Piezo1 channel in central nervous system disorders, such as Alzheimer's disease, multiple sclerosis, glaucoma, stroke, and glioma.
Supports
Endothelial Piezo1 channel mediates mechano-feedback control of brain blood flow
Abstract
Hyperemia in response to neural activity is essential for brain health. A hyperemic response delivers O2 and nutrients, clears metabolic waste, and concomitantly exposes cerebrovascular endothelial cells to hemodynamic forces. While neurovascular research has primarily centered on the front end of hyperemia-neuronal activity-to-vascular response-the mechanical consequences of hyperemia have gone largely unexplored. Piezo1 is an endothelial mechanosensor that senses hyperemia-associated forces. Using genetic mouse models and pharmacologic approaches to manipulate endothelial Piezo1 function, we evaluated its role in blood flow control and whether it impacts cognition. We provide evidence of a built-in brake system that sculpts hyperemia, and specifically show that Piezo1 activation triggers a mechano-feedback system that promotes blood flow recovery to baseline. Further, genetic Piezo1 modification led to deficits in complementary memory tasks. Collectively, our findings establish a role for endothelial Piezo1 in cerebral blood flow regulation and a role in its behavioral sequelae.
Supports
Local soft niches in mechanically heterogeneous primary tumors promote brain metastasis via mechanotransduction-mediated HDAC3 activity
Abstract
Tumor cells with organ-specific metastasis traits arise in primary lesions with substantial variations of local niche mechanics owing to intratumoral heterogeneity. However, the roles of mechanically heterogeneous primary tumor microenvironment in metastatic organotropism remain an enigma. This study reports that persistent priming in soft but not stiff niches that mimic primary tumor mechanical heterogeneity induces transcriptional reprogramming reminiscent of neuron and promotes the acquisition of brain metastatic potential. Soft-primed cells generate brain metastases in vivo through enhanced transendothelial migration across blood-brain barrier and brain colonization, which is further supported by the findings that tumor cells residing in local soft niches of primary xenografts exhibit brain metastatic tropism. Mechanistically, soft niches suppress cytoskeleton-nucleus-mediated mechanotransduction, which promotes histone deacetylase 3 activity. Inhibiting histone deacetylase 3 abolishes niche softness-induced brain metastatic ability. Collectively, this study uncovers a previously unappreciated role of local niche softness within primary tumors in brain metastasis, highlighting the significance of primary tumor mechanical heterogeneity in metastatic organotropism.
Supports
Mechanosensation of the heart and gut elicits hypometabolism and vigilance in mice
Abstract
Interoception broadly refers to awareness of one's internal milieu. Although the importance of the body-to-brain communication that underlies interoception is implicit, the vagal afferent signalling and corresponding brain circuits that shape perception of the viscera are not entirely clear. Here, we use mice to parse neural circuits subserving interoception of the heart and gut. We determine that vagal sensory neurons expressing the oxytocin receptor (Oxtr), referred to as NGOxtr, send projecti
Contradicts
Piezo-type mechanosensitive ion channel component 1: a mechano-bioenergetic transducer in the tumour microenvironment
Abstract
BACKGROUND/OBJECTIVES: As a pivotal mechanosensitive ion channel, Piezo-type mechanosensitive ion channel component 1 (Piezo1) converts mechanical stimuli into biochemical signals that regulate key oncogenic processes, including tumour cell proliferation, migration and invasion. Emerging evidence demonstrates that Piezo1 is widely expressed across various cellular compartments of the tumour microenvironment (TME), and its elevated expression strongly correlates with adverse clinical outcomes. A comprehensive understanding of the complex interactions between Piezo1 activation and cytokine networks in different TME cell populations is therefore essential for developing innovative and effective anti-tumour therapeutic strategies. In this review, we aimed to highlight the molecular mechanisms of Piezo1, systematically elucidating how the mechanical stimulation-Piezo1 signalling pathway within the TME contributes to tumour immune escape and malignant progression. Furthermore, we summarized current research advances in Piezo1-targeting drugs and clinical trials, and discuss strategies to improve tissue specificity while minimizing off-target effects. DISCUSSION: A comprehensive literature review was conducted, focusing on the specific mechanisms through which Piezo1 regulates endothelial cells, immune cells, cancer-associated fibroblasts and the extracellular matrix within the TME. Activation of Piezo1 in endothelial and immune cells promotes tumour angiogenesis and immune evasion.
Contradicts
Mechanosensitive ion channel Piezo1 mediates mechanical ventilation-exacerbated ARDS-associated pulmonary fibrosis
Abstract
INTRODUCTION: Pulmonary fibrosis is a major cause of the poor prognosis of acute respiratory distress syndrome (ARDS). While mechanical ventilation (MV) is an indispensable life-saving intervention for ARDS, it may cause the remodeling process in lung epithelial cells to become disorganized and exacerbate ARDS-associated pulmonary fibrosis. Piezo1 is a mechanosensitive ion channel that is known to play a role in regulating diverse physiological processes, but whether Piezo1 is necessary for MV-exacerbated ARDS-associated pulmonary fibrosis remains unknown. OBJECTIVES: This study aimed to explore the role of Piezo1 in MV-exacerbated ARDS-associated pulmonary fibrosis. METHODS: Human lung epithelial cells were stimulated with hydrochloric acid (HCl) followed by mechanical stretch for 48 h. A two-hitmodel of MV afteracidaspiration-inducedlunginjuryin mice was used. Mice were sacrificed after 14 days of MV. Pharmacological inhibition and knockout of Piezo1 were used to delineate the role of Piezo1 in MV-exacerbated ARDS-associated pulmonary fibrosis. In some experiments, ATP or the ATP-hydrolyzing enzyme apyrase was administered. RESULTS: The stimulation of human lung epithelial cells to HCl resulted in phenotypes of epithelial-mesenchymal transition (EMT), which were enhanced by mechanical stretching. MV exacerbated pulmonary fibrosis in mice exposed to HCl. Pharmacologicalinhibitionorknockout of Piezo1 attenuated the MV-exacerbated EMT process and lung fibrosis in vivo and in v
Contradicts
Mechanosensing by Piezo1 in gastric ghrelin cells contributes to hepatic lipid homeostasis in mice
Abstract
Ghrelin is an orexigenic peptide released by gastric ghrelin cells that contributes to obesity and hepatic steatosis. The mechanosensitive ion channel Piezo1 in gastric ghrelin cells inhibits the synthesis and secretion of ghrelin in response to gastric mechanical stretch. We sought to modulate hepatic lipid metabolism by manipulating Piezo1 in gastric ghrelin cells. Mice with a ghrelin cell-specific deficiency of Piezo1 (Ghrl-Piezo1-/-) had hyperghrelinemia and hepatic steatosis when fed a low-fat or high-fat diet. In these mice, hepatic lipid accumulation was associated with changes in gene expression and in protein abundance and activity expected to increase hepatic fatty acid synthesis and decrease lipid β-oxidation. Pharmacological inhibition of the ghrelin receptor improved hepatic steatosis in Ghrl-Piezo1-/- mice, thus confirming that the phenotype of these mice was due to overproduction of ghrelin caused by inactivation of Piezo1. Gastric implantation of silicone beads to induce mechanical stretch of the stomach inhibited ghrelin synthesis and secretion, thereby helping to suppress fatty liver development induced by a high-fat diet in wild-type mice but not in Ghrl-Piezo1-/- mice. Our study elucidates the mechanism by which Piezo1 in gastric ghrelin cells regulate hepatic lipid accumulation, providing insights into potential treatments for fatty liver.
Contradicts
Biophysical and mechanobiological considerations for T-cell-based immunotherapy
Abstract
Immunotherapies modulate the body's defense system to treat cancer. While these therapies have shown efficacy against multiple types of cancer, patient response rates are limited, and the off-target effects can be severe. Typical approaches in developing immunotherapies tend to focus on antigen targeting and molecular signaling, while overlooking biophysical and mechanobiological effects. Immune cells and tumor cells are both responsive to biophysical cues, which are prominent in the tumor micro
Contradicts
Emerging roles of mechanically activated ion channels in autoimmune disease
Abstract
Mechanically activated (MA) ion channels have rapidly gained prominence as vital conduits bridging aberrant mechanical cues in tissues with the dysregulated immune responses at the core of autoimmune diseases. Once regarded as peripheral players in inflammation, these channels, exemplified by PIEZO1, TRPV4, and specific K2P family members, now play a central role in modulating T-cell effector functions, B- cell activation and the activity of macrophages and dendritic cells. Their gating is intimately tied to physical distortions such as increased tissue stiffness, osmotic imbalances, or fluid shear, triggering a cascade of ionic fluxes that elevate proinflammatory signaling and drive tissue-destructive loops. Recognition of these channels as central mediators of mechanical stress-induced inflammation responses in autoimmune pathogenesis is rapidly expanding. In parallel, the emerging therapeutic strategies aim to restrain overactive mechanosensors or selectively harness them in affected tissues. Small molecules, peptide blockers, and gene-targeting approaches show preclinical promise, although off-target effects and the broader homeostatic roles of these channels warrant caution. This review explores how integrating mechanobiological concepts with established immunological paradigms enables a more detailed understanding of autoimmune pathogenesis. By elucidating how mechanical forces potentiate or dampen pathological immunity, we propose innovative strategies that exploit mec
Contradicts
5-HT3 receptors
Abstract
5-HT(3)-receptor antagonists are highly selective competitive inhibitors of the 5-HT(3)-receptor with negligible affinity for other receptors. They are potent, rapidly absorbed and easily penetrate the blood-brain barrier; metabolized by the cytochrome P450-system with half-life varying from 3-10 hours. The compounds investigated so far do not modify normal behaviour in animals or man and are well tolerated over wide dose ranges, the most common side effects being headache or constipation. Clinical efficacy was first established in chemotherapy-induced emesis (and then in radiotherapy-induced and post-operative emesis), where 5-HT(3)-receptor antagonists set a new standard of antiemetic efficacy and tolerability. The 5-HT(3) receptor antagonists, via a central and / or peripheral action, have been shown to reduce secretion and motility in the gut and possess clinical utility in irritable bowel syndrome, and possibly other visceral pain disorders. Their value in fibromyalgia is being evaluated. In preclinical behavioural assays they induce effects consistent with anxiolysis, improved cognition, anti-dopaminergic activity and use in drug abuse and withdrawal. There is some evidence that ondansetron may reduce alcohol consumption in moderate alcohol abusers but overall, 5-HT(3) receptor antagonists seem to be of limited use in psychiatric disorders: where effects have been seen, they seem to be unusually sensitive to dose and stage of disease. Nevertheless, their antiemetic pote
Contradicts
Astroglial Hmgb1 regulates postnatal astrocyte morphogenesis and cerebrovascular maturation
Abstract
Astrocytes are intimately linked with brain blood vessels, an essential relationship for neuronal function. However, astroglial factors driving these physical and functional associations during postnatal brain development have yet to be identified. By characterizing structural and transcriptional changes in mouse cortical astrocytes during the first two postnatal weeks, we find that high-mobility group box 1 (Hmgb1), normally upregulated with injury and involved in adult cerebrovascular repair, is highly expressed in astrocytes at birth and then decreases rapidly. Astrocyte-selective ablation of Hmgb1 at birth affects astrocyte morphology and endfoot placement, alters distribution of endfoot proteins connexin43 and aquaporin-4, induces transcriptional changes in astrocytes related to cytoskeleton remodeling, and profoundly disrupts endothelial ultrastructure. While lack of astroglial Hmgb1 does not affect the blood-brain barrier or angiogenesis postnatally, it impairs neurovascular coupling and behavior in adult mice. These findings identify astroglial Hmgb1 as an important player in postnatal gliovascular maturation.
Contradicts
[Neuromyelitis optica]
Abstract
BACKGROUND: Neuromyelitis optica (NMO) is a rare autoimmune inflammatory disease of the central nervous system that is characterized mainly by recurrent optic neuritis and longitudinally extensive transverse myelitis. The aim of this article is to present current knowledge on the clinical features, diagnosis, pathogenesis and treatment of the condition. METHOD: The article is based on a discretionary selection of English-language original articles, meta-analyses and review articles found in PubMed, and on the authors' own experience with the patient group. RESULTS: Neuromyelitis optica was previously assumed to be a variant of multiple sclerosis (MS), but the discovery of aquaporin-4 antibodies in patients with neuromyelitis optica has led to this view being revised. The cause of the condition is still unknown, but it has been shown that the antibodies bind selectively to a water channel expressed mainly on astrocytes at the blood-brain-barrier, which has an important role in the regulation of brain volume and ion homeostasis. Clinically, the condition presents as optic neuritis and/or transverse myelitis. A diagnosis is made on the basis of case history, clinical examination, MRI of the brain and spinal cord, analysis of cerebrospinal fluid, visual evoked potentials and a blood test with analysis of aquaporin-4 antibodies. Once a diagnosis has been made, rapid treatment is important. In the acute phase, intravenous methylprednisolone is recommended. There are several options
Contradicts
Piezo1: structural pharmacology and mechanotransduction mechanisms
Abstract
Piezo1, a mechanosensitive ion channel protein, is a highly promising target for drug development. We systematically review the latest advances in its structural features, signal transduction mechanisms, and functional roles in various pathological processes including neurological diseases, cardiovascular diseases, and cancer. Furthermore, we provide an in-depth analysis of three key challenges in developing Piezo1-targeted drugs, including the complexity of its dynamic structure and regulatory network, the difficulty of achieving specific targeting, and the off-target risks and potential systemic toxicity arising from its widespread physiological functions. Finally, we highlight that integrating cutting-edge technologies, such as super-resolution imaging, artificial intelligence (AI)-assisted drug design, and organoid/organ-on-a-chip models, holds great promise for overcoming these challenges and accelerating the development and clinical translation of Piezo1-targeted drugs.
Contradicts
Focused ultrasound excites cortical neurons via mechanosensitive calcium accumulation and ion channel amplification
Abstract
Ultrasonic neuromodulation has the unique potential to provide non-invasive control of neural activity in deep brain regions with high spatial precision and without chemical or genetic modification. However, the biomolecular and cellular mechanisms by which focused ultrasound excites mammalian neurons have remained unclear, posing significant challenges for the use of this technology in research and potential clinical applications. Here, we show that focused ultrasound excites primary murine cor
Contradicts
Direct pharmacological targeting of Piezo1 by Paeoniflorin: a novel therapeutic approach for renal fibrosis
Abstract
BACKGROUND: Renal fibrosis-characterized by microcirculatory disturbances and endothelial-mesenchymal transition (EndMT)-is a major pathological feature of chronic kidney disease (CKD) and remains a significant therapeutic challenge. The mechanosensitive ion channel Piezo1 plays a pivotal role in endothelial mechanotransduction and has been implicated in fibrogenesis, yet specific pharmacological interventions targeting Piezo1 are lacking. METHODS: We evaluated the renoprotective effects of paeoniflorin (PF), a bioactive monoterpene glycoside, in 5/6 nephrectomy-induced chronic renal failure (CRF) rats and diabetic kidney disease (DKD) db/db mice. PF-Piezo1 interactions were characterized using molecular docking, surface plasmon resonance (SPR), and functional assays. In vitro studies employing models of matrix stiffness, endothelial-fibroblast crosstalk, and HIF-1α inhibition were performed to elucidate the underlying mechanisms. RESULTS: PF treatment preserved renal function, reduced glomerulosclerosis, and ameliorated microvascular rarefaction in both CRF and DKD. Molecular docking and SPR analyses revealed that PF binds Piezo1 with high affinity, thereby inhibiting Yoda1-induced Ca2+ influx and attenuating stiffness-induced EndMT. PF restored the expression of endothelial markers including VE-cadherin and eNOS, and suppressed HIF-1α-mediated upregulation of Vimentin and TGF-β1. Moreover, co-culture experiments demonstrated that PF disrupted endothelial-derived TGF-β1 para
📖 Linked Papers (23)Export BibTeX ↗
Direct pharmacological targeting of Piezo1 by Paeoniflorin: a novel therapeutic approach for renal fibrosis.
Journal of advanced research (2026) · PubMed:40653265 ↗
9 figures
Figure 1
No caption available
Fig. 1
PF exhibits renoprotective effects in models of renal dysfunction (A) Schematic of experimental design. Sprague-Dawley (SD) rats were divided into four groups: ...
Mechanosensitive channel Piezo1 in calcium dynamics: structure, function, and emerging therapeutic strategies.
Frontiers in molecular biosciences (2025) · PubMed:41195420 ↗
1 figure
FIGURE 1
Piezo1 orchestrates the initiation and cascade of calcium signaling.
PIEZO1: a mechanosensitive ion channel in the pathogenesis and pharmacotherapy of diabetic neuropathy.
Molecular biology reports (2025) · PubMed:41051683 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
[Neuromyelitis optica].
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke (2013) · PubMed:24129537 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
5-HT3 receptors.
Current drug targets. CNS and neurological disorders (2004) · PubMed:14965242 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Piezo-type mechanosensitive ion channel component 1: a mechano-bioenergetic transducer in the tumour microenvironment.
Annals of medicine (2026) · PubMed:41437911 ↗
No figures
Mechano- and Glucocorticoid-Sensitive TREK-1 Channels Regulate Conventional Outflow and Intraocular Pressure.
Invest Ophthalmol Vis Sci (2025) · PubMed:41268978 ↗
No figures
Identification of mechanosensitive ion channel-related molecular subtypes and key genes for ovarian cancer.
Transl Cancer Res (2025) · PubMed:40950697 ↗
No figures
Corticosteroids elevate intraocular pressure through suppression of TREK-1 signaling.
bioRxiv : the preprint server for biology (2025) · PubMed:40894745 ↗
No figures
Piezo1: structural pharmacology and mechanotransduction mechanisms.
Trends in pharmacological sciences (2025) · PubMed:40750459 ↗
No figures
Emerging roles of mechanically activated ion channels in autoimmune disease.
Autoimmunity reviews (2025) · PubMed:40194731 ↗
No figures
📙 Related Wiki Pages (15)
acetylcholine-signaling-neurodegeneratiomechanismMicroglial Priming and Innate Immune ToltherapeuticSigma-1 Receptor Agonists for Neurodegentherapeuticmitochondrial-disease-neurodegenerationmechanismNatriuretic Peptide Receptor Modulators therapeuticPARP in NeurodegenerationmechanismmiRNA Regulatory Pathway in NeurodegenermechanismTunneling Nanotubes in NeurodegenerationmechanismProtein Aggregation Comparison in NeurodmechanismBrain Pericytes in NeurodegenerationcellGSK3 Beta in NeurodegenerationmechanismEpigenetic Dysregulation in NeurodegenermechanismFLT3/FLT3L Cytokine Therapy for NeurodegtherapyNT-3 Signaling Pathway in NeurodegeneratmechanismRibonuclease κ and Circular RNAs: A New mechanism
🏥 Translation
🧬 3D Protein Structure — PIEZO1
No curated PDB or AlphaFold mapping for PIEZO1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for PIEZO1 and KCNK2 from GTEx v10.
💉 Clinical Trials (5)Relevance: 44%
0
Active
Active
0
Completed
Completed
282
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
RAPA-501 Therapy for ALSPHASE2
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for PIEZO1 and KCNK2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
2.5 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 3.7%
Volatility
Medium
0.0214
Events (7d)
6
Price History
▼21.8%💾 Resource Usage
LLM Tokens
16,394
$0.0984
Total Cost
$0.0984
🧭 Related
🕸 Knowledge Subgraph (167 edges)Showing top 50 of 167 edges by weightCentered on PIEZO1 and KCNK2
Top relations:co discussed (118)co associated with (21)participates in (10)associated with (8)interacts with (6)targets (3)
🔍 Show all 50 edges across 5 relations
associated with (5)
co discussed (26)
🗺️ KG Entities (36)
APOEAQP4Astrocyte reactivity signalingBDNFBMAL1C1QC3Circadian clock / BMAL1-CLOCK transcriDGAT1DGAT1 and SOAT1Epigenetic regulationGDNFHK2Insulin/IGF metabolic signalingKCNK2MIRO1Mitochondrial dynamics / bioenergeticsP2RX7P2RY1P2RY1 and P2RX7PIEZO1PIEZO1 and KCNK2Purinergic signalingRESTSOAT1SOD1TAUTET2TIMP1TNFh-0758b337h-7d4a24d3h-db6aa4b1neurodegenerationprocessedsess_SDA-2026-04-10-sda-2026-04-01-gap
🧪 Adjacent Hypotheses10 siblings from the same analysis
Epigenetic Memory Erasure via TET2 Activation
0.74TET2 · neurodegeneration · debated
Metabolic Switch Targeting for A1→A2 Repolarization
0.73HK2 · neurodegeneration · debated
Circadian Rhythm Entrainment of Reactive Astrocytes
0.72BMAL1 · neurodegeneration · debated
Purinergic Signaling Polarization Control
0.71P2RY1 and P2RX7 · neurodegeneration · debated
Mitochondrial Transfer Pathway Enhancement
0.70MIRO1 · neurodegeneration · debated
Lipid Droplet Dynamics as Phenotype Switches
0.67DGAT1 and SOAT1 · neurodegeneration · debated
Metabolic Memory Reprogramming via Molecular Switches
0.00Undefined · proposed
GLP-1R-Astrocyte Axis for Cognitive Rescue
0.00GLP1R · proposed
Bioenergetic Checkpoint Modulation for Astrocyte Fate Control
0.00AMPK/MTOR/SIRT1 · proposed
ARAP3-Mediated Microglial-Astrocyte Cross-Talk Modulation
0.00ARAP3 · proposed
🗣 Debate PerspectivesGap Analysis | 5 rounds | 2026-04-01
🔮 Predictions
🔎 Predictions vs Observations3 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention utilize randomized, placebo-controlled design with primary endpoints of cognitive stabilization (CDR-SB change <0 | utilize randomized, placebo-controlled design with primary endpoints of cognitive stabilization (CDR-SB change <0 | — no observation — | pending | 0.55 |
| If hypothesis is true, intervention affect concurrent medications | affect concurrent medications | — no observation — | pending | 0.55 |
| If hypothesis is true, intervention employ dose escalation from 25-200 mg daily of P1X-101, with primary endpoints including adverse events, pharmacokinetics, and target engagement measured by CSF YKL | employ dose escalation from 25-200 mg daily of P1X-101, with primary endpoints including adverse events, pharmacokinetics, and target engagement measured by CSF | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (3)
pendingconf 55%
If hypothesis is true, intervention employ dose escalation from 25-200 mg daily of P1X-101, with primary endpoints including adverse events, pharmacokinetics, and target engagement measured by CSF YKL-40 reduction
Predicted outcome: employ dose escalation from 25-200 mg daily of P1X-101, with primary endpoints including adverse events, pharmacokinetics, and target engagement measu
Falsification: Intervention fails to employ dose escalation from 25-200 mg daily of P1X-101, with primary endpoints including adverse events, pharmacokinetics, and target engagement measured by CSF YKL-40 reduction
pendingconf 55%
If hypothesis is true, intervention utilize randomized, placebo-controlled design with primary endpoints of cognitive stabilization (CDR-SB change <0
Predicted outcome: utilize randomized, placebo-controlled design with primary endpoints of cognitive stabilization (CDR-SB change <0
Falsification: Intervention fails to utilize randomized, placebo-controlled design with primary endpoints of cognitive stabilization (CDR-SB change <0
pendingconf 55%
If hypothesis is true, intervention affect concurrent medications
Predicted outcome: affect concurrent medications
Falsification: Intervention fails to affect concurrent medications
📖 References (11)
- Identification of mechanosensitive ion channel-related molecular subtypes and key genes for ovarian cancer.Zhang L et al.. Transl Cancer Res (2025)
- Inflammation alters the expression and activity of the mechanosensitive ion channels in periodontal ligament cells.Ren J et al.. Eur J Orthod (2024)
- Mechano- and Glucocorticoid-Sensitive TREK-1 Channels Regulate Conventional Outflow and Intraocular Pressure.Redmon SN et al.. Invest Ophthalmol Vis Sci (2025)
- Corticosteroids elevate intraocular pressure through suppression of TREK-1 signaling.Redmon SN et al.. bioRxiv : the preprint server for biology (2025)
- Mechanosensitive channel Piezo1 in calcium dynamics: structure, function, and emerging therapeutic strategies.Liu Y et al.. Frontiers in molecular biosciences (2025)
- PIEZO1: a mechanosensitive ion channel in the pathogenesis and pharmacotherapy of diabetic neuropathy.Gupta T et al.. Molecular biology reports (2025)
- Piezo-type mechanosensitive ion channel component 1: a mechano-bioenergetic transducer in the tumour microenvironment.["Zhang Y" et al.. Annals of medicine (2026)
- Mechanosensitive ion channel Piezo1 mediates mechanical ventilation-exacerbated ARDS-associated pulmonary fibrosis.["Fang X" et al.. Journal of advanced research (2023)
- Mechanosensing by Piezo1 in gastric ghrelin cells contributes to hepatic lipid homeostasis in mice.["Zhang J" et al.. Science signaling (2024)
- Biophysical and mechanobiological considerations for T-cell-based immunotherapy.["Zhuang C" et al.. Trends in pharmacological sciences (2023)
- Emerging roles of mechanically activated ion channels in autoimmune disease.["Zeng Z" et al.. Autoimmunity reviews (2025)
Related Entities
▸Metadata
| status | proposed |
| _schema_version | 1 |
| hypothesis_type | None |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
1
Incoming
4323
Outgoing
3005
0 supporting
0 contradicting
1 neutral
🌍 Provenance Graph
20 nodes, 139 edges
derives from (14)
hypothesis-h-db6aa4b1→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-0758b337hypothesis-h-0758b337→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-d2722680hypothesis-h-d2722680→analysis-SDA-2026-04-01-gap-00
▸ Show 9 more
analysis-SDA-2026-04-01-gap-00→hypothesis-h-db6aa4b1analysis-SDA-2026-04-01-gap-00→hypothesis-h-a1b56d74hypothesis-h-a1b56d74→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-5706bbd7hypothesis-h-5706bbd7→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-7d4a24d3hypothesis-h-7d4a24d3→analysis-SDA-2026-04-01-gap-00analysis-SDA-2026-04-01-gap-00→hypothesis-h-969bd8e0hypothesis-h-969bd8e0→analysis-SDA-2026-04-01-gap-00
supports (24)
hypothesis-h-db6aa4b1→paper-40950697paper-40950697→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-39789885paper-39789885→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-41268978
▸ Show 19 more
paper-41268978→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-40894745paper-40894745→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-41195420paper-41195420→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-41051683paper-41051683→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-31596529paper-31596529→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-39722451paper-39722451→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-37532007paper-37532007→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-39375369paper-39375369→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-40009679paper-40009679→hypothesis-h-db6aa4b1hypothesis-h-db6aa4b1→paper-39824919paper-39824919→hypothesis-h-db6aa4b1
🗣 Debate History1 session
gap_analysisWhat are the mechanisms underlying astrocyte reactivity subtypes in neurodegeneration?r5q=0.952026-04-01
This artifact has no version history yet.
Linked Artifacts (7311)
🧬 Related Hypotheses — same target / disease (20)
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.924 · Target: NLRP3, CASP1, IL1B, PYCARD · neurodegeneration
APOE-Dependent Autophagy Restoration
Score: 0.895 · Target: MTOR · neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 · Target: SLC16A1, SLC16A7, LDHA, PDHA1 · neurodegeneration
p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphoryla
Score: 0.895 · Target: MAPK14/PRMT1 · neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 · Target: SIRT1 · neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 · Target: TREM2 · neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial
Score: 0.887 · Target: IFNG · neurodegeneration
TREM2-APOE Axis Dissociation for Selective DAM Activation
Score: 0.886 · Target: TREM2-APOE axis · neurodegeneration
Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
Score: 0.882 · Target: HCRTR1/HCRTR2 · neurodegeneration
Complement Cascade Inhibition Synaptic Protection
Score: 0.867 · Target: — · neurodegeneration
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Tran
Score: 0.862 · Target: NAMPT · neurodegeneration
H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State
Score: 0.856 · Target: EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B · neurodegeneration
Senescent Cell ASM-Complement Cascade Intervention
Score: 0.852 · Target: SMPD1 · neurodegeneration
Prime Editing Precision Correction of APOE4 to APOE3 in Microglia
Score: 0.850 · Target: APOE · neurodegeneration
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease
Score: 0.847 · Target: TREM2 · neurodegeneration
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection
Score: 0.844 · Target: TYROBP · neurodegeneration
Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration
Score: 0.844 · Target: SMPD3 · neurodegeneration
miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Mic
Score: 0.843 · Target: MIR155 · neurodegeneration
Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome
Score: 0.839 · Target: SST, SSTR1, SSTR2 · neurodegeneration
Gamma Oscillation Enhancement Synergy
Score: 0.838 · Target: — · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-db6aa4b1?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[Mechanosensitive Ion Channel Reprogramming](http://scidex.ai/artifact/hypothesis-h-db6aa4b1)
Direct URL
http://scidex.ai/artifact/hypothesis-h-db6aa4b1
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.